Cara Therapeutics to Present at November Investor Conferences
November 12 2019 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced company
management will present a corporate overview at two investor
conferences in November:
Stifel 2019 Healthcare Conference (New
York, NY)Date: Tuesday, November 19,
2019Time: 4:10 p.m. ET
Jefferies 2019 London Healthcare
Conference (London, UK)Date: Thursday,
November 21, 2019Time: 5:20 p.m. GMT (12:20 p.m.
ET)
A live audio webcast of each event can be
accessed under "Events & Presentations" in the News &
Investors section of the Company's website
at www.CaraTherapeutics.com. An archived webcast recording
will be available on the Cara website for approximately 30
days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that
targets KORs located in the peripheral nervous system, and on
immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA
(CR845/difelikefalin) Injection has demonstrated statistically
significant reductions in itch intensity and concomitant
improvement in pruritus-related quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP), and is currently being
investigated in Phase 3 trials in hemodialysis patients with
CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of
pruritus in patients with chronic kidney disease, atopic
dermatitis, and primary biliary cholangitis.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:Jane
UrheimStern Investor Relations, Inc. 212-362-1200
jane.urheim@SternIR.com
MEDIA CONTACT:Annie Starr6
Degrees973-415-8838 astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024